{"product_id":"89bio-five-forces-analysis","title":"89bio Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003e89bio faces intense R\u0026amp;D and regulatory pressures typical of biopharma, with supplier concentration for reagents and strong buyer scrutiny from payers and partners. Competitive rivalry is shaped by niche pipeline differentiation, while capital intensity and clinical risk moderate threats of new entrants and substitutes. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore 89bio’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated biologics CDMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing pegozafermin requires specialized biologics CDMOs with FGF21 and PEGylation capabilities. The pool of high-quality suppliers is limited—2024 leaders include Lonza, Catalent, Samsung Biologics and WuXi Biologics—giving them leverage on price, slots and tech-transfer terms. Dual-sourcing is difficult due to process complexity, so any capacity crunch or quality issue can delay trials and commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCritical raw materials and reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCritical inputs for 89bio such as PEGylation polymers, chromatography resins, single-use systems and regulatory-grade cell banks are supplied by a handful of dominant vendors (Sartorius, Cytiva, Thermo Fisher), creating supplier leverage. Lead times frequently run 12–24 weeks and master cell bank development often takes 6–12 months, enhancing negotiation power. Securing long-term supply agreements and safety stocks is essential, and regulatory-grade documentation further locks in specific suppliers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs, clinical sites, and KOL networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetition for NASH biopsy-capable sites and experienced CROs is intense as the global CRO market was estimated at $62.5 billion in 2024, driving premium pricing for specialized hepatology expertise. Top hepatology centers and KOLs can dictate timelines, budgets, and protocol nuances, with biopsy screen-failure rates for NASH trials commonly reported around 50%, creating enrollment bottlenecks that raise per-patient costs and sponsor dependence. Preferred partnerships and site networks can partially offset supplier bargaining power by securing faster enrollment and negotiated rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized analytics and biomarkers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialized analytics and biomarkers (MRI-PDFF, histopathology reads, bioanalytical assays) are niche services with limited global providers; while over 26,000 CLIA-certified labs exist in the US (2024), few meet consistent regulatory standards for multicenter trials, so switching labs risks assay drift and data discontinuity, increasing supplier leverage on price and service terms.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMRI-PDFF: limited qualified sites\u003c\/li\u003e\n\u003cli\u003eHigh switching risk: assay drift, lost continuity\u003c\/li\u003e\n\u003cli\u003eSupplier power: pricing and contract terms rise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold-chain logistics and fill-finish\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePegozafermin requires strict cold-chain stability and sterile fill-finish under rigorous QA; qualified biologics CDMOs are concentrated and booking windows are often many months, giving suppliers leverage. Process deviations can lead to batch loss and regulatory holds, amplifying supplier power, so long-term capacity reservations are strategically important.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConcentrated qualified CDMOs\u003c\/li\u003e\n\u003cli\u003eBooking windows: many months\u003c\/li\u003e\n\u003cli\u003eDeviations risk batch loss and regulatory holds\u003c\/li\u003e\n\u003cli\u003eLong-term capacity reservations critical\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO bottlenecks heighten supply risk — \u003cstrong\u003e12–24 weeks\u003c\/strong\u003e lead times, premium CRO pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManufacturing pegozafermin depends on a small set of CDMOs (Lonza, Catalent, Samsung, WuXi) and specialized vendors, giving suppliers strong leverage with 12–24 week lead times and MCB timelines of 6–12 months. Niche CRO\/hepatology capacity and biomarker labs (26,000 CLIA labs in US, few qualified for NASH) plus a $62.5B CRO market (2024) drive premium pricing and switching risk. Long-term contracts and capacity reservations are essential to mitigate delays.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal CRO market\u003c\/td\u003e\n\u003ctd\u003e$62.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS CLIA labs\u003c\/td\u003e\n\u003ctd\u003e26,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO lead times\u003c\/td\u003e\n\u003ctd\u003e12–24 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMCB dev.\u003c\/td\u003e\n\u003ctd\u003e6–12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter’s Five Forces overview for 89bio highlighting competitive rivalry, buyer and supplier influence on pricing, barriers deterring new entrants, threats from substitutes and disruptive biotech innovations, and implications for 89bio’s market positioning and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA clear one-sheet Porter's Five Forces for 89bio—distills competitive threats, supplier\/buyer power, substitutes, and entry barriers into a concise view for rapid, boardroom-ready decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and HTA bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayers and HTA bodies will demand robust histologic and hard clinical outcomes for NASH and CV risk reduction in SHTG, driven by NAFLD\/NASH affecting ~25% of the global population. High budget impact from this large patient pool intensifies price scrutiny and access controls, making outcomes-based contracts likely. Clear superiority versus GLP-1s or THR-beta agents would materially reduce buyer leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialists and treatment centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHepatologists, endocrinologists and lipidologists act as prescribing gatekeepers for 89bio, comparing efficacy, tolerability, dosing convenience and combo potential; specialists account for \u0026gt;50% of advanced NASH specialty prescriptions. Strong guideline inclusion and KOL advocacy historically increase uptake and can cut buyer bargaining power by shifting demand to manufacturers. Conversely, complex monitoring requirements—labs, imaging, specialist follow‑up—raise centers' leverage and slow adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient affordability and adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInjectable biologics face pronounced co-pay sensitivity, with studies through 2024 reporting up to 30% of patients delaying or abandoning high-cost biologics for affordability reasons, creating adherence friction. Patient assistance programs and simpler dosing regimens can boost uptake but transfer cost pressure to manufacturers and payers, often cutting patient out-of-pocket by \u0026gt;50%. If oral or lifestyle options (fibrates, omega-3s) are acceptable and cheaper, buyers gain leverage. Clear symptomatic and TG reductions in SHTG can blunt price sensitivity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcurement consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePBMs and specialty pharmacies aggregate demand and negotiate large rebates for 89bio therapies; the top 3 US PBMs control roughly 80% of prescription volume, specialty drugs now drive about 50% of US drug spend, and rebates for biologics\/specialty classes often reach 30–40%. Formulary tiering and prior authorization increase buyer leverage, real-world evidence is shaping renewal and value-based terms (now ~10% of commercial deals), and narrow networks further compress net pricing.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePBM concentration ~80%\u003c\/li\u003e\n\u003cli\u003eSpecialty = ~50% of spend\u003c\/li\u003e\n\u003cli\u003eRebates often 30–40%\u003c\/li\u003e\n\u003cli\u003eValue-based contracts ~10%\u003c\/li\u003e\n\u003cli\u003eNarrow networks compress net pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndication mix and unmet need\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpnash presents vast unmet need up to of adults with nafld and an estimated progressive nash patient heterogeneity drives payer selectivity restricts broad formulary access. shtg shows clearer biomarker-defined response reductions enabling tighter value propositions targeted reimbursement. higher clinical differentiation lowers buyer power ambiguous endpoints variability in strengthen it.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNASH prevalence: up to 25% adults, progressive NASH ~3–5%\u003c\/li\u003e\n\u003cli\u003eSHTG: biomarker-driven response supports targeted value\u003c\/li\u003e\n\u003cli\u003eClinical differentiation reduces customer bargaining power\u003c\/li\u003e\n\u003cli\u003eAmbiguous endpoints increase payer selectivity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pnash\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNAFLD drugs face payer pressure: outcomes-based deals, PBM rebates, and monitoring burdens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayers\/HTAs demand hard outcomes; NAFLD affects ~25% of adults, driving price scrutiny and outcomes-based deals. Specialists and guideline placement can lower buyer power, but monitoring burden and copay sensitivity give payers and patients leverage. PBM concentration (~80%) and rebates (30–40%) amplify negotiating clout, while clear clinical differentiation reduces it.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNAFLD prevalence\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgressive NASH\u003c\/td\u003e\n\u003ctd\u003e3–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM concentration (top 3)\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty drug spend\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical rebates\u003c\/td\u003e\n\u003ctd\u003e30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue-based deals\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003e89bio Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact 89bio Porter's Five Forces Analysis you'll receive immediately after purchase—no surprises, no placeholders. The document displayed is the same professionally written, fully formatted analysis ready for download and use the moment you buy. You're looking at the actual deliverable with instant access upon payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eivalry Among Competitors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApproved and late-stage NASH competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMadrigal’s resmetirom, with reported ~50% relative liver‑fat reduction and ~20% LDL drop in pivotal data, sets a regulatory and commercial benchmark in MASH\/NASH with fibrosis, raising the bar for approval and pricing; THR‑beta class competition intensifies positioning pressure for FGF21 analogs (showing fibrosis signal across trials), creating near head‑to‑head expectations and forcing differentiation on fibrosis endpoints, lipids and non‑invasive markers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFGF21 class peers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkero’s efruxifermin is a direct class competitor to 89bio with overlapping NASH\/MAFLD indications, making head-to-head comparisons on liver fat, fibrosis regression, and metabolic endpoints central to rivalry. Safety profile, dosing frequency, and durability of response will likely decide market share. Subtle trial design differences—endpoints, biopsy timing, and patient selection—can markedly shift perceived advantage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMetabolic powerhouses with incretin platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk and Eli Lilly push GLP-1\/GIP agents with clear liver‑fat and weight benefits—STEP-1 semaglutide showed ~14.9% mean weight loss and SURMOUNT-1 tirzepatide ~22.5%—intensifying competition. Lifecycle and combo strategies target overlapping patient pools, raising share stakes. Primary care distribution of these agents challenges specialty biologics. Superior NASH histology or combo synergy could blunt that advantage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSHTG lipid-lowering innovators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpionis apoc3 programs showed up to tg reductions in trials while angptl3 yields declines these benchmarks raise the bar for shtg differentiation. safety signals pancreatitis-risk reduction and cv outcomes will determine market share restrictive labels or rems can quickly shift advantage. class=\"lst_crct\"\u003e\u003cli\u003eAPOC3: ~70% TG ↓ (2024)\u003c\/li\u003e\u003cli\u003eANGPTL3\/evinacumab: ~30–50% TG ↓\u003c\/li\u003e\u003cli\u003eKey: safety, pancreatitis, CV data, label\/REMS\u003c\/li\u003e\n\u003c\/pionis\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRace for payer and guideline mindshare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFirst-to-market status and guideline inclusion create durable advantages for 89bio, anchoring payer preference and a higher baseline price realization; top three PBMs cover about 70% of US prescription claims (2024), amplifying the payoff for early coverage. Real-world data and HEOR will decide formulary placement and utilization management. Companion diagnostics or NITs can franchise use by making switching costly. Sales force scale and strategic partnerships magnify these effects.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFirst-to-market: guideline lock-in\u003c\/li\u003e\n\u003cli\u003eRWE\/HEOR: formulary battlegrounds, PBMs ~70% (2024)\u003c\/li\u003e\n\u003cli\u003eCompanion diagnostics\/NITs + sales scale = durable uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong liver-fat and LDL efficacy raises bar as GLP-1\/GIP overlap and PBM control shape market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMadrigal’s resmetirom (~50% liver‑fat ↓, ~20% LDL ↓) sets a high regulatory\/commercial bar, intensifying direct THR‑beta and FGF21 rivalry; Akero’s efruxifermin and GLP1\/GIP (semaglutide ~14.9% weight ↓, tirzepatide ~22.5%) create overlapping indications. Lipid programs (APOC3 ~70% TG ↓, ANGPTL3 30–50%) raise differentiation needs; PBM\/formulary control (~70% US claims) will decide share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResmetirom\u003c\/td\u003e\n\u003ctd\u003e~50% liver‑fat ↓; ~20% LDL ↓\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSemaglutide\u003c\/td\u003e\n\u003ctd\u003e~14.9% weight ↓\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTirzepatide\u003c\/td\u003e\n\u003ctd\u003e~22.5% weight ↓\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPOC3\u003c\/td\u003e\n\u003ctd\u003e~70% TG ↓\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eANGPTL3\u003c\/td\u003e\n\u003ctd\u003e30–50% TG ↓\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eSubstitutes Threaten\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLifestyle modification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiet, exercise and weight loss are first-line low-cost therapy; guidelines target 7–10% weight loss which in trials reduced liver fat and improved histology, and can lower triglycerides by ~20–30%. Real-world sustained weight-loss ≥5% at 1 year occurs in ~20–30% of patients, highlighting adherence challenges. Payers often require 6–12 month documented lifestyle trials before covering drugs, making this a persistent substitute for milder disease.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGLP-1\/GIP and other metabolic drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGLP-1\/GIP agents (tirzepatide\/semaglutide) deliver up to ~20%+ weight loss and 30–60% hepatic fat reductions in trials, sometimes achieving sufficient metabolic control to obviate NASH-specific therapy. Oral THR-beta (resmetirom) offers a pill alternative with meaningful steatosis reductions in late‑stage trials. SGLT2s, pioglitazone and vitamin E remain niche options for subsets. Convenience and lower cost can displace injectables absent clear superior outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBariatric and endoscopic procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSurgical and endoscopic weight-loss interventions deliver durable metabolic benefits, with bariatric procedures producing average total weight loss of 20–35% and diabetes remission rates up to 60–80% at 1–5 years. For eligible patients studies show NASH resolution in ~50–60% and meaningful dyslipidemia improvements. High upfront costs ($15k–$35k) but superior efficacy pose a strong substitute to drugs. Limited access, eligibility criteria and perioperative risks constrain broad substitution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmega-3 and lipid therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHigh-dose EPA (4 g\/day) and EPA-combination products are entrenched for hypertriglyceridemia; REDUCE-IT reported ~25% relative risk reduction in major adverse CV events and high-dose EPA yields ~20–30% TG lowering in SHTG cohorts. These agents are familiar and widely accessible, while multiple generic omega-3s exert strong price pressure versus branded therapies. 89bio needs clear superiority on TG lowering and hard outcomes to avoid substitution.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e25% RRR in REDUCE-IT vs placebo\u003c\/li\u003e\n\u003cli\u003e20–30% TG lowering with high-dose EPA\u003c\/li\u003e\n\u003cli\u003eGenerics often \u0026gt;50% cheaper, driving price pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupportive care and watchful waiting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupportive care and watchful waiting act as a meaningful substitute for 89bio by enabling clinicians to defer pharmacologic intervention when patients are asymptomatic or lack coverage; global NAFLD prevalence is about 25% of adults and roughly 20% of those have NASH, creating a large pool managed conservatively in 2024. Monitoring with noninvasive tests (NITs) and lifestyle advice can cover short-term needs, undermining uptake in borderline fibrosis cases, though robust phase 2\/3 data showing fibrosis progression reduction would reduce this threat.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNAFLD prevalence ~25% (2024)\u003c\/li\u003e\n\u003cli\u003eNASH among NAFLD ~20%\u003c\/li\u003e\n\u003cli\u003eWatchful waiting common for asymptomatic\/borderline fibrosis\u003c\/li\u003e\n\u003cli\u003eStrong antifibrotic evidence can reverse substitution risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGLP-1\/GIP ~\u003cstrong\u003e20%+\u003c\/strong\u003e WL vs bariatric \u003cstrong\u003e20–35%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLow-cost lifestyle therapy achieves sustained ≥5% weight loss in ~20–30% at 1 year, often required by payers. GLP-1\/GIP drugs deliver ~20%+ weight loss; oral resmetirom and generics offer cheaper pill options. Bariatric surgery yields 20–35% total weight loss at $15k–$35k. NAFLD prevalence ~25% in 2024; ~20% of NAFLD have NASH.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLifestyle\u003c\/td\u003e\n\u003ctd\u003e20–30% ≥5% WL at 1 yr\u003c\/td\u003e\n\u003ctd\u003eHigh payor barrier\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLP-1\/GIP\u003c\/td\u003e\n\u003ctd\u003e~20%+ WL\u003c\/td\u003e\n\u003ctd\u003eStrong clinical substitute\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBariatric\u003c\/td\u003e\n\u003ctd\u003e20–35% WL; $15k–$35k\u003c\/td\u003e\n\u003ctd\u003eDurable, limited access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003entrants Threaten\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh clinical and regulatory hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNASH phase 3 programs typically enroll 1,500–3,000 patients, run 48–72 weeks with liver biopsy or validated NITs, and can cost $200–500M, creating major capital barriers. High failure rates in late-stage NASH and the lack of an FDA-approved antifibrotic therapy as of 2024 deter new entrants. Evolving FDA\/EMA guidance on surrogate endpoints and antifibrotic evidence increases regulatory complexity and risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and CMC complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEngineering stable, scalable PEGylated FGF21 biologics is technically demanding, with formulation and conjugation challenges that extend development timelines. GMP capacity, advanced analytics, and comparability testing create high fixed barriers and supplier lead times that in 2024 commonly exceed 9–12 months. New entrants face long qualification windows for suppliers and CROs, and CMC setbacks frequently add 12–24 months or can derail programs entirely.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP, data, and class know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy 2024 89bio faces patent thickets around FGF21 designs, formulations, and dosing—dozens of issued and pending claims that raise freedom-to-operate analyses, adding months and typically $0.5–2M in legal and clearance costs. Clinical know-how and KOL relationships built across FGF21 trials are cumulative advantages that newcomers can rarely match quickly. Elevated litigation risk, with patent suits often costing millions, further deters entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial access and payer evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuilding payer dossiers, HEOR programs and outcomes evidence requires multi-year, multi-million-dollar investment, limiting entrants that lack head-to-head trials or robust RWE and thereby restricting commercial access for new competitors in 2024. Established players set pricing anchors that shape formularies and reimbursement thresholds, while sophisticated contracting and value-based arrangements act as a commercial moat.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBarriers: high HEOR\/RWE cost\u003c\/li\u003e\n\u003cli\u003eEvidence: lack of head-to-head limits access\u003c\/li\u003e\n\u003cli\u003ePricing: incumbents set anchors\u003c\/li\u003e\n\u003cli\u003eMoat: advanced contracting sophistication\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital markets and partner dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical-stage biotechs depend on volatile capital markets and selective big‑pharma partnerships; with venture and public financing down (biotech VC investment fell about 28% from the 2021 peak to 2024) and alliance deals increasingly milestone‑driven, funding gates and partner selectivity materially reduce the threat of new entrants.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh capital intensity\u003c\/li\u003e\n\u003cli\u003e~28% drop in VC funding (2021–2024)\u003c\/li\u003e\n\u003cli\u003eMilestone‑based big‑pharma deals\u003c\/li\u003e\n\u003cli\u003eShort cash runways limit new entrants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh NASH Phase 3 costs and long timelines plus patent and supply hurdles deter entrants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh capital and long development timelines (NASH phase 3: $200–500M, 48–72 weeks) create strong entry barriers. Complex CMC, PEG‑FGF21 formulation challenges and supplier lead times (9–12 months) raise technical risk. Patent thickets and legal clearance (~$0.5–2M) plus −28% biotech VC funding (2021–2024) and milestone deals reduce entrant threat.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNASH Phase 3 cost\u003c\/td\u003e\n\u003ctd\u003e$200–500M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial duration\u003c\/td\u003e\n\u003ctd\u003e48–72 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier lead times\u003c\/td\u003e\n\u003ctd\u003e9–12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent\/legal cost\u003c\/td\u003e\n\u003ctd\u003e$0.5–2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVC funding change\u003c\/td\u003e\n\u003ctd\u003e−28% (2021–2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097835213148,"sku":"89bio-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/89bio-five-forces-analysis.png?v=1781787170","url":"https:\/\/pestel-analysis.com\/products\/89bio-five-forces-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}